Skip to NavigationSkip to content


Clinigen becomes sole license holder of cancer drug Proleukin in $210m deal

Novartis has arranged to sell the remainder of its rights to its skin and lung cancer drug Proleukin (aldesleukin, recombinant interleukin-2) to Clinigen in a deal worth $210 million, it has emerged.

The agreement breaks down into an initial payment by Clinigen of $120 million, with $60 million to follow deferred over the 12 months following the deal’s completion. The rest will be paid in milestone payments, subject to sales performance.

Clinigen shares soar after $210m Novartis cancer drug deal

British company Clinigen has bought the rights to sell Novartis’ cancer drug Proleukin in the United States in a deal worth $210 million.

Clinigen, a growing speciality pharma group, already sells Proleukin outside of the US. Proleukin is used to treat metastatic kidney cancer and metastatic melanoma.

Clinigen will pay an initial sum of $120 million for the US rights alongside a further $60 million which will be differed for a year. The remaining $30 million will be paid dependent on the drug reaching certain sales milestones.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches